Answers are grounded in this paper and cite their sources.
Lung cancer is the most common cancer and cause of cancer death worldwide.1 At diagnosis, 20-35% of patients with non-small cell lung cancer (NSCLC) have locally advanced (LA) disease.2 Patients with LA-NSCLC who are not surgical candidates are generally offered chemoradiation (chemoRT) followed by durvalumab per the PACIFIC trial (if EGFR and ALK negative). PACIFIC demonstrated an overall survival (OS) benefit,3,4 though with an 18-month progression-free survival of 44.2%, many patients are not cured.
No takes yet. Share an insight, caveat, or question.
Sharp et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: